Taken together, these results suggest that one to two weekly subcutaneous injections of saline containing 20 μM of XMD8-92 is sufficient to halt diabetes-mediated VEGF production in the retina, which is a prevalent precursor to the onset of diabetic retinopathy. This evidence concerns the gene VEGFA and diabetic retinopathy.